Catalog Number 94640 |
Device Problem
Improper or Incorrect Procedure or Method (2017)
|
Patient Problem
Patient Problem/Medical Problem (2688)
|
Event Date 11/09/2016 |
Event Type
malfunction
|
Manufacturer Narrative
|
Further information from the reporter regarding event, product, or patient details has been requested.No additional information is available at this time.Device labeling addresses the reported event(s) as follows: "precautions ¿ juvéderm voluma® xc is to be used as supplied.Modification or use of the product outside the directions for use may adversely impact the sterility, homogeneity, and performance of the product.".
|
|
Event Description
|
Healthcare professional reported that approximately 4 months after injection in the peri-orbital area and marionette lines with one syringe of juvéderm voluma® xc, the patient experienced a ¿possible granuloma, nodules and swelling.¿ the symptoms were in the area of injection as well as "a lot of the face." approximately 4.5 months after injection the patient was injected with hylenex.The patient was also treated with antibiotics, medrol dosepak, steroid injection, and an oral steroid.The patient also took some tetracycline which had not been prescribed.The juvéderm voluma® xc was diluted 1:1 with saline.A company healthcare professional noted that the physiological events are considered not device related given the injector reported the product was ¿diluted 1:1 with saline¿.Approximately 2 months after injection patient was injected to the lips with juvéderm volbella® xc but had no adverse events in that area.
|
|
Manufacturer Narrative
|
Device history record summary: the release step combined with the absence of any deviation shows that no element could explain these reactions: all the manufacturing steps and all the physicochemical and microbiological results (endotoxins, bioburden) are registered as conforming to the specifications.The sterilization cycle is registered as conforming.The extrusion force value shows an expected consistency of the product.
|
|
Event Description
|
Additional information: upon further follow up with healthcare professional, it was indicated that, ¿additional treatments with hylenex x 7¿ were provided an undetermined time after the initial treatment with hylenex.Kenalog was administered approximately 2 months after the first hylenex treatment.
|
|
Event Description
|
Further follow up with the healthcare professional revealed that symptoms resolved approximately 7 months after injection occurred.
|
|
Search Alerts/Recalls
|